Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P07355
UPID:
ANXA2_HUMAN
Alternative names:
Annexin II; Annexin-2; Calpactin I heavy chain; Calpactin-1 heavy chain; Chromobindin-8; Lipocortin II; Placental anticoagulant protein IV; Protein I; p36
Alternative UPACC:
P07355; Q567R4; Q6N0B3; Q8TBV2; Q96DD5; Q9UDH8
Background:
Annexin A2, known by various names such as Annexin II and Lipocortin II, is a calcium-regulated membrane-binding protein. It exhibits a high affinity for calcium, significantly enhanced by anionic phospholipids, and binds two calcium ions with high affinity. Annexin A2 plays a crucial role in various cellular processes, including the heat-stress response. It is also known to inhibit PCSK9-enhanced LDLR degradation, potentially reducing PCSK9 protein levels through a translational mechanism and competing with LDLR for PCSK9 binding.
Therapeutic significance:
Understanding the role of Annexin A2 could open doors to potential therapeutic strategies. Its ability to modulate PCSK9-enhanced LDLR degradation suggests a promising avenue for the development of novel treatments for cholesterol-related disorders.